.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Exploring Recent Developments in the Treatment of Patients with HR+ Metastatic Breast Cancer

EP. 1: Dr. Graff on Initial Steps for Treating Metastatic HR-Positive Breast Cancer

August 8th 2022

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.

EP. 2: Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

August 9th 2022

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

EP. 3: Dr. Litton on Remaining Questions in ESR1-Mutated Breast Cancer

September 7th 2022

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.

EP. 4: Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer

October 7th 2022

A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.